Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.
作者信息
Lipsky Andrew H, Lozier Jay N, Wiestner Adrian
机构信息
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD Department of Internal Medicine, Montefiore Medical Center, Bronx, New York, NY, USA.
Department of Laboratory Medicine, NIH Clinical Center, Bethesda, MD.
出版信息
Haematologica. 2016 Mar;101(3):e124-5. doi: 10.3324/haematol.2015.140558.
Abstract
摘要
相似文献
1
Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.对关于接受依鲁替尼治疗的慢性淋巴细胞白血病患者出血相关不良事件的发生率和危险因素的评论的回应。
Haematologica. 2016 Mar;101(3):e124-5. doi: 10.3324/haematol.2015.140558.
2
Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.对利普斯基等人的评论：接受依鲁替尼治疗的慢性淋巴细胞白血病患者出血相关不良事件的发生率及危险因素
Haematologica. 2016 Mar;101(3):e123. doi: 10.3324/haematol.2015.139030.
3
PO-54 - Clinical and laboratory characterization of platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia.PO-54 - 伊布替尼治疗慢性淋巴细胞白血病患者引起的血小板功能障碍的临床和实验室特征。
Thromb Res. 2016 Apr;140 Suppl 1:S196. doi: 10.1016/S0049-3848(16)30187-6. Epub 2016 Apr 8.
4
Massive oral bleeding after full-mouth extraction in a patient with B-cell lymphocytic leukemia/small lymphocytic lymphoma reversed with recombinant activated factor VII.一名B细胞淋巴细胞白血病/小淋巴细胞淋巴瘤患者在全口拔牙后出现大量口腔出血，使用重组活化因子VII后出血得到逆转。
J Am Dent Assoc. 2016 Feb;147(2):142-5. doi: 10.1016/j.adaj.2015.09.001. Epub 2015 Nov 6.
5
Ibrutinib in chronic lymphocytic leukaemia: alone or in combination?伊布替尼用于慢性淋巴细胞白血病：单独使用还是联合使用？
Lancet Oncol. 2016 Feb;17(2):129-131. doi: 10.1016/S1470-2045(15)00519-7. Epub 2015 Dec 5.
6
Bleeding complications in chronic lymphocytic leukaemia.
Acta Univ Palacki Olomuc Fac Med. 1990;125:121-6.
7
The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.伊布替尼在慢性淋巴细胞白血病治疗中的新作用。
Expert Rev Hematol. 2013 Oct;6(5):543-6. doi: 10.1586/17474086.2013.831324. Epub 2013 Oct 2.
8
Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.467例B细胞慢性淋巴细胞增殖性疾病患者的表型异常发生率：用于微小残留病研究的特定四色染色设计基础
Leukemia. 2002 Aug;16(8):1460-9. doi: 10.1038/sj.leu.2402584.
9
Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting: commentary.第60届美国血液学会年会慢性淋巴细胞白血病亮点：述评
Clin Adv Hematol Oncol. 2019 Jan;17 Suppl 1(1):20-23.
10
Response to Comment by Amato T. .对阿马托·T.评论的回应
Haematologica. 2019 Nov;104(11):e541. doi: 10.3324/haematol.2019.224303.
引用本文的文献
1
Successful Management of Ibrutinib-Induced Thrombocytopenia in a Patient with Chronic Lymphocytic Leukemia: No Interruption, Only Reduction.慢性淋巴细胞白血病患者中依鲁替尼所致血小板减少症的成功管理：无需中断，只需减量。
Turk J Haematol. 2024 Mar 1;41(1):55-56. doi: 10.4274/tjh.galenos.2023.2023.0426. Epub 2023 Dec 22.
2
Abivertinib inhibits megakaryocyte differentiation and platelet biogenesis.阿比维替尼抑制巨核细胞分化和血小板生成。
Front Med. 2022 Jun;16(3):416-428. doi: 10.1007/s11684-021-0838-5. Epub 2021 Nov 18.
3
Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.布鲁顿酪氨酸激酶抑制剂与心脏毒性：不止是房颤。
Curr Oncol Rep. 2021 Aug 3;23(10):113. doi: 10.1007/s11912-021-01102-1.
4
Managing toxicities of Bruton tyrosine kinase inhibitors.布鲁顿酪氨酸激酶抑制剂的毒性管理。
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):336-345. doi: 10.1182/hematology.2020000118.
本文引用的文献
1
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.接受依鲁替尼治疗的慢性淋巴细胞白血病患者出血相关不良事件的发生率及危险因素
Haematologica. 2015 Dec;100(12):1571-8. doi: 10.3324/haematol.2015.126672. Epub 2015 Oct 1.
2
Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.依鲁替尼抑制血小板整合素 αIIbβ3 外向信号和血栓稳定性，但不抑制与胶原的黏附。
Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2326-35. doi: 10.1161/ATVBAHA.115.306130. Epub 2015 Sep 10.
3
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.伊布替尼抑制胶原介导的血小板聚集，但不抑制 ADP 介导的血小板聚集。
Leukemia. 2015 Apr;29(4):783-7. doi: 10.1038/leu.2014.247. Epub 2014 Aug 20.
4
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.伊布替尼与奥法妥木单抗治疗既往治疗的慢性淋巴细胞白血病。
N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.
5
CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia.CD39活性与慢性淋巴细胞白血病的分期相关，并抑制血小板反应性。
J Transl Med. 2007 May 4;5:23. doi: 10.1186/1479-5876-5-23.
6
Platelet function in chronic leukemias.慢性白血病中的血小板功能
Indian J Cancer. 1992 Jun;29(2):49-55.
Zotero 插件